Parte del contenido permanece en su idioma original hasta que se revise su traducción.
Qué está en tendencia · AT A GLANCE
AbbVie’s 53‑Year Dividend Streak Highlights Long‑Term Stability
THE TAKEAWAY
The Globe and Mail notes AbbVie’s 53‑year record of dividend increases, contrasting it with Pfizer’s 5.9% yield, suggesting AbbVie’s long‑term dividend growth may appeal to investors seeking stability.
Reported development
AbbVie has maintained a dividend increase streak for 53 years, according to The Globe and Mail.
Why it matters
The 53‑year dividend streak signals a sustained commitment to returning value to shareholders, which can be attractive for income‑focused investors. The comparison with Pfizer’s 5.9% yield highlights a trade‑off between higher current yield and long‑term dividend growth potential.
Watch next
Monitoring AbbVie’s quarterly earnings releases for any changes to its dividend policy will clarify whether the 53‑year streak continues.
Supporting analysis & reasoning
News sentiment · ABBVIE · Positive
The reported 53‑year dividend increase streak reflects a positive view of AbbVie’s long‑term shareholder return strategy.
Source headlines
- Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy? - The Globe and Mail · The Globe and Mail · 14 Nov 2026, 14:26 Dubai